Patents by Inventor Marcos W. Steinberg

Marcos W. Steinberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of use
    Patent number: 9700606
    Abstract: The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., antibodies) that bind to the HVEM cis complexes.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: July 11, 2017
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Carl F. Ware, Timothy C. Cheung, Marcos W. Steinberg
  • Compositions and methods for modulating responses mediated or associated with BTLA activity
    Patent number: 8349320
    Abstract: Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). A novel binding site for BTLA is disclosed, located in cysteine-rich domain-1 of HVEM. BTLA binding site on HVEM overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D (gD), but is distinct from where LIGHT binds, yet gD inhibits the binding of both ligands. A BTLA activating protein present in human cytomegalovirus is identified as UL144. UL144 binds BTLA, but not LIGHT, and inhibits T cell proliferation.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: January 8, 2013
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventors: Carl F. Ware, Carl De Trez, Michael Croft, Timothy C. Cheung, Ian R. Humphreys, Karen G. Potter, Christopher A. Benedict, Mitchell Kronenberg, Marcos W. Steinberg
  • HVEM/BTLA, HVEM/CD 160 AND HVEM/GD CIS COMPLEXES AND METHODS OF USE
    Publication number: 20110123551
    Abstract: The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., antibodies) that bind to the HVEM cis complexes.
    Type: Application
    Filed: July 8, 2009
    Publication date: May 26, 2011
    Inventors: Carl F. Ware, Timothy C. Cheung, Marcos W. Steinberg
  • US CIP-COMPOSITIONS AND METHODS FOR MODULATING RESPONSES MEDIATED OR ASSOCIATED WITH BTLA ACTIVITY
    Publication number: 20100104559
    Abstract: Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). A novel binding site for BTLA is disclosed, located in cysteine-rich domain-1 of HVEM. BTLA binding site on HVEM overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D (gD), but is distinct from where LIGHT binds, yet gD inhibits the binding of both ligands. A BTLA activating protein present in human cytomegalovirus is identified as UL144. UL144 binds BTLA, but not LIGHT, and inhibits T cell proliferation.
    Type: Application
    Filed: June 10, 2009
    Publication date: April 29, 2010
    Inventors: Carl F. Ware, Carl De Trez, Michael Croft, Timothy C. Cheung, Ian R. Humphreys, Karen G. Porter, Christopher A. Benedict, Mitchell Kronenberg, Marcos W. Steinberg